iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 807

Identifiers

  • Canonical SMILES: 
    CCN(CC)C(=O)[C@H](N1[C@@H](c2ccc(Cl)cc2)C(=O)N(CCCCC(O)=O)c2ccc(I)cc2C1=O)c1ccc(Cl)cc1
  • IUPAC name: 
    5-[3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-(diethylamino)-2-oxoethyl]-7-iodo-2,5-dioxo-3H-1,4-benzodiazepin-1-yl]pentanoic acid
  • InChi: 
    InChI=1S/C32H32Cl2IN3O5/c1-3-36(4-2)31(42)28(20-8-12-22(33)13-9-20)38-29(21-10-14-23(34)15-11-21)32(43)37(18-6-5-7-27(39)40)26-17-16-24(35)19-25(26)30(38)41/h8-17,19,28-29H,3-7,18H2,1-2H3,(H,39,40)/t28-,29+/m1/s1
  • InChiKey: 
    MHOPTQKTBICWMN-WDYNHAJCSA-N

External links


168318072
23271216

External search

Bibliography (1)

Publication Name
Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T. . Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorganic & medicinal chemistry letters. 16

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 0 0

Targets

PPI family Best activity Diseases MMoA
MDM2-Like / P53 5.67 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 735.08 g/mol
HBA 8
HBD 1
HBA + HBD 9
AlogP 6.36
TPSA 98.23
RB 11
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 2 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
16600594 16 MDM2
Q00987
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 5.67
16600594 16 MDM2
Q00987
Cellular assay Proliferation assay MCF7 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 5.05
16600594 16 MDM2
Q00987
Cellular assay Proliferation assay MDA MB321 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 4.43
Ta Structure Name Drugbank ID
0.5357 4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid DB08581
0.5322 Bentiromide DB00522
0.5281 Ombitasvir DB09296
0.5152 [(2S)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid DB08717
0.5141 Delparantag DB12955
0.5127 4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide DB08344
0.5062 OPC-28326 DB05461
0.5060 Dexloxiglumide DB04856
0.5031 Balicatib DB12239
0.4948 Repaglinide DB00912
0.4911 [1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER DB07956
0.4897 CP-320626 DB03383
0.4889 N-(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)-4-morpholin-4-yl-4-oxobutanamide DB08582
0.4868 IMG-7289 DB15126
0.4857 AGG-523 DB15460